Hypersensitivity, Silent Inactivation, and Premedication Strategies for Pegaspargase in AYA ALL

Dr. Silverman discusses the evolution of premedication practice for pegaspargase in AYA ALL, noting that the CALGB 10403 trial incorporated a protocol amendment requiring premedication after hypersensitivity events became frequent during accrual. Premedication before pegaspargase infusion has since become standard adult practice to reduce hypersensitivity reactions. In contrast, pediatric practice has historically avoided routine premedication due to concern that it could mask hypersensitivity symptoms and lead to missed detection of silent inactivation. Dr. Curran confirms that pediatric practice still shows variability, with premedication decisions often left to institutional discretion.

Dr. Curran explains the critical distinction between hypersensitivity and silent inactivation. True hypersensitivity produces clinical symptomatology (urticaria, flushing, bronchospasm, angioedema) mediated by neutralizing antibodies that also inactivate the drug. Silent inactivation occurs when neutralizing antibodies develop without clinical allergic symptoms, meaning the patient appears to tolerate therapy normally but asparaginase is not producing measurable enzyme activity or asparagine depletion. Silent inactivation can only be detected through therapeutic drug monitoring.

Premedication that suppresses hypersensitivity symptoms creates 2 problems: it may mask true hypersensitivity in patients who would otherwise be identified as having antibody-mediated drug inactivation, and it does nothing for patients with silent inactivation who never develop symptoms in the first place. Giving premedication without concurrent therapeutic drug monitoring risks administering biologically inactive asparaginase without detection. Dr. Silverman and Dr. Curran both conclude that premedication is appropriate and reasonable, but only in the context of routine TDM to confirm ongoing drug activity. Hypersensitivity occurs in approximately 10% to 20% of pediatric patients receiving asparaginase, confirming that this is a clinically frequent event requiring systematic detection strategies.